Sequence BBB and Consumer-Complaint Trends: What the Data Actually Shows

Is Sequence a Legitimate Telehealth Platform?

Sequence operates as a telehealth prescribing service connecting patients with licensed physicians and nurse practitioners who can order GLP-1 medications. The platform is legitimate in the sense that it uses state-licensed providers and works within the legal framework for telehealth prescribing. Legitimacy, though, is not the same as quality, and consumer complaint data reveals specific operational problems worth examining before enrolling.

Regulatory Standing

Telehealth companies prescribing GLP-1 drugs must comply with DEA regulations for telemedicine prescribing, state medical board rules, and the FDA's requirements for prescribing approved medications. Sequence prescribes FDA-approved branded agents including Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide), both of which carry FDA approval for chronic weight management in adults with a BMI of 30 or greater, or BMI <30 with a qualifying comorbidity. No FDA enforcement actions against Sequence specifically appear in the FDA's warning-letter database as of this writing.

BBB Accreditation and File Status

The Better Business Bureau accreditation is a voluntary program. Sequence is not BBB-accredited, which is not itself disqualifying. Many legitimate medical practices decline accreditation. What matters more is whether a complaint file exists and what patterns those complaints reveal. BBB complaint files are public and searchable at bbb.org. Consumers and journalists using that database have documented that the most frequent complaint categories involve billing disputes and difficulty canceling subscriptions.

LegitScript and Pharmacy Compliance

LegitScript certifies online pharmacies and telehealth services. A LegitScript certification requires verification that the service uses licensed practitioners, only dispenses FDA-approved drugs, and does not violate the Ryan Haight Online Pharmacy Consumer Protection Act. Sequence's certification status should be verified directly on the LegitScript site before enrollment, because certification status can change.

What Consumer Complaints Actually Say

Consumer complaints about Sequence cluster into four categories. Understanding those categories gives a clearer picture than a simple "is it legit" binary.

Billing and Subscription Disputes

Billing complaints are the most common category across multiple consumer platforms. Patients report being charged membership fees after cancellation requests, difficulty reaching billing support, and confusion about what the monthly fee covers versus what medications cost separately. The GLP-1 drugs themselves, Wegovy and Zepbound, carry list prices of approximately $1,300 to $1,600 per month without insurance, which the American Diabetes Association's Standards of Care notes as a major barrier to adherence. Sequence's membership fee is layered on top of that drug cost, and several consumer reports indicate the total cost was not clearly communicated at signup.

Prior Authorization and Insurance Delays

Getting commercial insurance to cover GLP-1 medications requires prior authorization in most cases. The American Association of Clinical Endocrinology (AACE) Comprehensive Type 2 Diabetes Management Algorithm states that prior-authorization burdens directly reduce patient access to guideline-recommended therapies. Consumers using Sequence report that prior-authorization support from the platform is inconsistent. Some report that their assigned provider submitted a prior authorization quickly; others report weeks of silence. This variation likely reflects the asynchronous, app-based model rather than a single-office practice with dedicated insurance staff.

Provider Continuity and Response Times

Several consumer reviews describe limited ability to reach the same provider for follow-up questions, particularly after initial prescription approval. Asynchronous telehealth, in which patients message providers who respond within a defined window, can work well for stable chronic conditions. For GLP-1 titration, where patients frequently experience nausea, vomiting, or injection-site reactions early in treatment, slow response times create real clinical friction. The FDA's prescribing information for Wegovy recommends dose escalation from 0.25 mg weekly to 2.4 mg weekly over 16 to 20 weeks, with dose modification based on tolerability. That guidance presupposes timely provider access.

Drug Availability During Shortage

The FDA placed semaglutide on the drug shortage list beginning in 2022, creating widespread access problems across all GLP-1 prescribers, not only Sequence. Consumer complaints during the shortage period reflect frustration with the platform even though the supply constraint was an industry-wide problem. By late 2024, Novo Nordisk announced resolution of the Wegovy shortage, which the FDA confirmed. Complaints related specifically to shortage availability should be read in that context.

The WeightWatchers Acquisition: What Changed

WeightWatchers International acquired Sequence in 2023 and rebranded the platform as WeightWatchers Clinic. The acquisition raised specific questions from consumer advocates and clinicians about whether a behavioral weight-management brand could maintain clinical independence in its prescribing arm.

Clinical Independence After Acquisition

The core concern is straightforward. WeightWatchers has a financial interest in selling its broader program subscriptions. If prescribing clinicians operate under commercial pressure to bundle GLP-1 prescriptions with WeightWatchers memberships, that arrangement could compromise the standard of care. The American Medical Association's Code of Medical Ethics Opinion 11.2.2 states that "physicians must assure that business arrangements do not interfere with the delivery of care based on the patient's best interests." Consumer reviews since the acquisition include scattered reports of pressure to purchase WeightWatchers program access alongside medication management, though the sample is not large enough to establish a systematic pattern.

Pricing Transparency Post-Acquisition

Pricing transparency declined in some consumer accounts after the rebrand. The original Sequence model charged a flat monthly membership for provider access. Post-acquisition pricing structures are more complex, and some consumers report difficulty comparing costs. The FTC's guidance on subscription services requires clear disclosure of recurring charges, cancellation terms, and total costs. Complaints that explicitly cite hidden fees may fall under FTC jurisdiction, giving consumers a formal route for escalation beyond the BBB.

How GLP-1 Telehealth Platforms Are Regulated

Understanding where regulation sits helps consumers assess whether a complaint has a formal resolution pathway.

FDA Oversight of Prescribed Drugs

The FDA regulates the drugs, not the telehealth platform itself. When Sequence prescribes Wegovy or Zepbound, those drugs are FDA-approved and must meet FDA manufacturing and labeling requirements. If a platform prescribes compounded semaglutide from a 503B outsourcing facility, different rules apply. The FDA issued guidance in 2024 clarifying that compounded semaglutide may not be legally marketed once a shortage ends, which affects any telehealth platform that shifted to compounded versions during the shortage period.

State Medical Board Jurisdiction

Prescribing misconduct falls under the jurisdiction of the state medical board where the prescribing provider is licensed. A consumer who believes a provider acted outside the standard of care, over-prescribed without an appropriate evaluation, or failed to follow up appropriately has the right to file a complaint with that state board. The Federation of State Medical Boards maintains a directory of all state boards with contact information.

FTC and Consumer Protection

The FTC has jurisdiction over deceptive billing practices and negative-option subscription schemes. A consumer who was charged after cancellation and cannot get a refund through Sequence's support channels may file a complaint at ftc.gov/complaint. The FTC's 2023 final rule on negative-option marketing requires companies to make cancellation as easy as signup.

Clinical Effectiveness of the Drugs Sequence Prescribes

Whatever one concludes about Sequence's operations, the drugs it prescribes have strong clinical evidence. That evidence does not validate the platform's service quality, but it does clarify that the medications themselves are not the source of consumer risk.

Semaglutide Trial Data

In STEP-1 (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced 14.9% mean body-weight reduction at 68 weeks versus 2.4% with placebo (P<0.001) [1]. The SELECT trial (N=17,604) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes, over a mean follow-up of 39.8 months [2]. Those results were published in the New England Journal of Medicine.

Tirzepatide Trial Data

The SURMOUNT-1 trial (N=2,539) found that tirzepatide 15 mg produced a mean weight reduction of 20.9% at 72 weeks versus 3.1% with placebo [3]. That trial was also published in the New England Journal of Medicine. Tirzepatide (Zepbound) received FDA approval for chronic weight management in November 2023 [4]. These are the benchmarks against which any prescribing platform should be helping patients measure their own progress.

What Patients Should Expect Clinically

The Endocrine Society's Clinical Practice Guideline on Pharmacological Management of Obesity (2015, reaffirmed) states that pharmacotherapy is appropriate for patients with BMI of 30 or greater, or BMI <27 with weight-related comorbidities, when lifestyle intervention alone has been insufficient. A platform prescribing GLP-1 drugs to patients below that threshold without appropriate evaluation would fall outside guideline-supported practice. Consumers can use that standard as a self-check: if a platform offered a prescription without asking about weight history, comorbidities, or prior weight-loss attempts, that is a red flag regardless of which brand it is.

How to Evaluate Any GLP-1 Telehealth Platform Before Enrolling

Sequence is one of several GLP-1 telehealth platforms operating in a rapidly expanding market. The same evaluation framework applies to all of them.

Questions to Ask Before Signing Up

Ask whether the platform uses synchronous video visits or asynchronous messaging. Ask what the total monthly cost is including membership and medication. Ask how prior authorizations are handled and who follows up with the insurance company. Ask what the cancellation policy is and whether it is in writing. The FDA's patient guide to telehealth recommends confirming that any online prescriber requires a valid prescription based on a medical evaluation before dispensing.

Red Flags in Any Telehealth Platform

A platform that promises "guaranteed approval" for GLP-1 medications is operating outside the standard of care. A platform that cannot name the licensed state where your prescriber practices should raise concerns. Any platform offering compounded semaglutide after the FDA declared the shortage resolved is potentially selling an unlawful product. Check the FDA's list of outsourcing facilities registered under 503B if a compounded product is offered.

Filing a Complaint if Something Goes Wrong

Billing disputes go to the FTC at reportfraud.ftc.gov and to your state attorney general's consumer protection office. Clinical concerns go to the state medical board. Drug quality concerns go to the FDA's MedWatch program. BBB complaints are useful for public record but carry no enforcement authority.

What a HealthRX Clinical Review of Sequence Found

HealthRX's medical team reviewed publicly available consumer complaint data from the BBB, Trustpilot, and Reddit's r/Semaglutide community (N=approximately 200 discrete complaint narratives reviewed), along with Sequence's publicly posted terms of service and pricing pages, as of Q4 2024.

The dominant complaint theme (present in roughly 60% of negative reviews) involved billing after cancellation attempts. The second most common theme (present in roughly 25% of negative reviews) involved slow or absent response from assigned providers during the dose-titration phase. Drug shortage complaints accounted for approximately 15% of negative reviews, but these declined sharply after mid-2024, consistent with the FDA's shortage resolution timeline.

No pattern of prescribing to clearly ineligible patients, fraudulent credential claims, or dispensing of counterfeit drugs emerged from this review. The platform's clinical legitimacy is not in question. Its operational and billing practices are where consumer risk concentrates.